NeoGenomics (NEO) Cut Its Losses In Q3, Is The 26% Undervaluation Case Convincing?

NeoGenomics (NEO) just posted third quarter 2026 results that showed higher sales of US$209.25 million and a sharply smaller net loss of US$7.55 million, putting its oncology diagnostics focus in the spotlight for investors.

The earnings update has landed alongside a share price of US$16.84, with a 1 month share price return of 5.12% and a year to date share price gain of 43.20% that points to momentum building around NeoGenomics. However, the 1 year total shareholder return of 67.06% contrasts with a weaker 5 year total shareholder return that remains deeply underwater.

Scan how NeoGenomics compares to other cancer testing and healthcare diagnostics players by reviewing our curated list of 35 healthcare AI stocks for potential momentum and quality.

Bulls see NeoGenomics turning shrinking losses and steady cancer testing demand into a reset story. Bears point to ongoing losses and a bruising 5 year track record. Which side does the current valuation back up?

Most Popular Narrative: 26% Undervalued

NeoGenomics is trading at $16.84 while the most followed narrative framework points to a fair value of about $22.89. The gap on paper is meaningful and puts the focus on whether its execution can keep up with expectations.

Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage, supporting future expansion in EBITDA margins and earnings growth.

See why 6 investors see NeoGenomics as 26% undervalued.

Result: Fair Value of $22.89 (UNDERVALUED)

Still, pressure on pharma and biotech demand, and any stumble in product launches like PanTracer, could quickly weaken the case for NeoGenomics’ current discount.

Find out about the key risks to this NeoGenomics narrative.

Another View: NeoGenomics Looks Pricey On Sales

While the popular NeoGenomics narrative leans on a fair value of about $22.89, the simple sales based yardstick tells a tougher story. The stock trades on a P/S of 2.8x, which is more than double the US Healthcare average of 1.2x and above the peer group at 1.4x.

The fair ratio for NeoGenomics is estimated at 1.6x P/S, well below where the shares change hands today. That gap points to real multiple risk if sentiment cools, so the key question is whether you think margins and growth can keep the valuation at a premium.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether the mixed signals around NeoGenomics add up to opportunity or just noise for you personally? Move quickly, stress test the thesis against the underlying numbers, and then weigh that against the 1 important warning sign.

Looking for more investment ideas beyond NeoGenomics?

If NeoGenomics has your attention, do not stop here. Broaden your watchlist, test different angles, and let fresh ideas compete for your capital.

• Target resilience first and scan a 31 resilient stocks with low risk scores that focuses on businesses with more defensive risk profiles and steadier fundamentals.
• Hunt for mispriced quality and review a 19 high quality undiscovered gems that brings lesser known but fundamentally sound opportunities onto your radar.
• Prioritise financial strength and run a list of solid balance sheet and fundamentals (25 results) that filters for sturdier balance sheets and healthier core metrics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com